AstraZeneca Buys Priority Review Voucher With Two Big Filings On The Horizon

AstraZeneca paid $95m to Swedish Orphan Biovitrum for the voucher, which it could use to expedite the FDA review of roxadustat or trastuzumab deruxtecan.

YONKERS, NY - CIRCA 1990's: Sculpture of race between the tortoise and hare from Aesop's Bench, Yonkers, NY - Image
AstraZeneca buys a priority review • Source: Shutterstock

AstraZeneca PLC has its sights set on speeding up the US Food and Drug Administration review of an upcoming new drug filing. The company revealed on 22 August that it paid $95m to buy a priority review voucher from Swedish Orphan Biovitrum AB.

An FDA priority review cuts the timeline for reviewing a new drug from 10 months to six months, excluding the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip